Likopid tab 1mg 10 pc

Description

Composition
Active substance:
1 tablet contains: glyukozaminilmuramildipeptid (GMDP) – 1.0 mg.
Excipients:
Lactose monohydrate – 73.88 mg, sugar (sucrose) – 5.0 mg potato starch – 19.0 mg, methylcellulose – 0.12 mg Calcium Stearate – 1.0 mg.
Description:
Round Valium pills white beveled.
Product form:
The tablets of 1 mg.
10 tablets in blisters made of PVC film and aluminum foil printed patent. 1 contour cellular packaging together with instructions for medical application is placed in a pile of cardboard.
Contraindications
Hypersensitivity to glyukozaminilmuramildipeptidu and other ingredients; Pregnancy and lactation; autoimmune thyroiditis exacerbation; state, accompanied by febrile temperature (> 38 ° C) at the time of taking the drug; rare inborn errors of metabolism: alaktaziya, galactosemia, lactase deficiency, lactose intolerance, lack of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption; application in autoimmune diseases is not recommended due to lack of clinical data.
Dosage
1 mg
Indications
The drug is used in adults and children (from 3 years) in the treatment of diseases associated with secondary immunodeficiency states:
Children: – chronic, recurrent infections of the upper and lower airway in the acute stage and in a remission stage; – acute and chronic suppurative inflammatory diseases of the skin and soft tissue (pyoderma, furunculosis, etc.); – herpes infection.
Adults: – chronic respiratory tract infections; – acute and chronic suppurative inflammatory diseases of the skin and soft tissue (pyoderma, furunculosis, etc.); – herpes infection.
Prophylactic administration (adults): – prevention and reducing seasonal incidence of acute respiratory infections and exacerbations of chronic diseases of upper respiratory tract, upper and lower respiratory tract.
Interaction with other drugs
The preparation increases the effectiveness of antimicrobial agents, there is synergy with antiviral or antifungal agents. Antacids and sorbents significantly reduce the bioavailability of the drug. Glucocorticosteroids Likopida® reduce the biological effect.
Overdose
Cases of overdose are unknown.
Based on the pharmacological properties of the drug, in the case of overdose can be observed rise in body temperature to subfebrile (up to 37,9 ° C) values. If necessary the symptomatic therapy (antipyretics) are assigned sorbents. A specific antidote is not known.
pharmachologic effect
Pharmacological group:
Immunomodulatory agent.
Pharmacological properties:
The active substance pellets Likopid® – glyukozaminilmuramildipeptid (GMDP) – is a synthetic analogue of structural fragment membranes (peptidoglycan) bacterial cells. GMDP is an activator of the innate and acquired immunity, increases the body’s defense against viral, bacterial and fungal infections; providing adjuvant effect in the development of immunological reactions.
Biological activity of the preparation is realized by binding to an intracellular receptor GMDP protein NOD2, localized in the cytoplasm of phagocytes (neutrophils, macrophages, dendritic cells). The preparation stimulates the functional (bactericidal, cytotoxic) activity of phagocytes, enhances the presentation of antigens, proliferation of T and B lymphocytes, increases the synthesis of specific antibodies helps to normalize balance of Th1 / Th2-lymphocytes in the predominance of Th1. Pharmacological action performed by the gain generating key interleukins (interleukin-1, interleukin-6, interleukin-12), tumor necrosis factor alpha, interferon gamma, colony stimulating factors. The drug increases the activity of natural killer cells.
Likopid® low toxicity (LD50 greater than therapeutic dose of 106, 000 times or more). In the experiment, the oral route of administration at doses 100 times exceeding the therapeutic one, the drug has no toxic effect on the central nervous and cardiovascular systems, does not cause the pathological changes of the internal organs. Likopid® has no embryotoxicity or teratogenic effects, does not cause chromosome, gene mutations. In experimental studies conducted on animals, provided data on the antitumor activity Likopida® (GMDP).
Pharmacokinetics:
The bioavailability of the drug when orally reception is 7-13%. The degree of binding to albumin blood weak. The time to reach maximum concentration (tmax) – 1,5 hours after reception. The half-life (t1 / 2) – 4.29 hours. Active metabolites does not form, derived mainly via the kidneys in unchanged form.
Pregnancy and breast-feeding
Admission Likopid® 1 mg of the drug is contraindicated in women during pregnancy and breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
Frequently (1-10%) – at the beginning of the treatment can be observed a transient increase in body temperature to subfebrile values ​​(up to 37,9 ° C) that is not an indication to remove the drug.
Rarely (0.01-0.1%) – transient increase in body temperature to febrile values ​​(> 38,0 ° C). With an increase in body temperature over 38,0 ° C can receive antipyretics that does not diminish the pharmacological effects Likopid® tablets.
Very rare (less than 0.01%) – diarrhea.
If any of these instructions side effects are compounded, or if you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
Each tablet contains 1 mg Likopid® sucrose in an amount of 0.00042 HE (Bread units) that patients should be considered diabetic.
Each tablet contains 1 mg Likopid® 0.074 grams lactose, which should be considered for patients suffering hypolactasia (lactose intolerance, in which the body is observed decline in lactase – enzyme necessary for digesting lactose).
It does not affect the ability to drive and complex mechanisms.
Storage conditions
In a dry place, protected from light at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Likopid® administered orally or sublingually empty stomach, 30 minutes before meals.
At the admission of the drug if it has been less than 12 hours from the scheduled time, you can take the missed dose; in the case if more than 12 hours on a scheduled reception time, it is necessary to take only the following scheme dose not accept skipped.
Dose adjustment for individual patient groups (the elderly, patients with impaired liver function, patients with impaired renal function) is required.
Children:
Acute and chronic suppurative inflammatory diseases of the skin and soft tissue (pyoderma, furunculosis, and others): 1 tablet 1 per day sublingual for 10 days.
Chronic, recurrent infections of the upper and lower respiratory tract infections (acute stage and in a remission stage) Likopid® 3 courses take 1 tablet 1 per day sublingual for 10 days with an interval between the courses 20 days.
Herpetic infection: 1 tablet 3 times a day orally or sublingually for 10 days.
Adults:
Chronic respiratory tract infections: 2 tablets 1 time per day under the tongue for 10 days.
Acute and chronic suppurative inflammatory diseases of the skin and soft tissue (pyoderma, furunculosis, and others): 2 tablets 2-3 times daily under the tongue for 10 days.
Herpetic infection: 2 tablets 3 times a day orally or sublingually for 10 days.
Prevention (adult): 1. for preventing or reducing the incidence of acute respiratory disease and seasonal exacerbations diseases of upper respiratory tract, upper and lower respiratory tract Likopid® take 1 tablet, 3 times a day under the tongue for 10 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist